Cargando…
Lung cancer organoids: models for preclinical research and precision medicine
Lung cancer is a malignancy with high incidence and mortality rates globally, and it has a 5-year survival rate of only 10%–20%. The significant heterogeneity in clinical presentation, histological features, multi-omics findings, and drug sensitivity among different lung cancer patients necessitate...
Autores principales: | Liu, Yajing, Zhou, Yanbing, Chen, Pu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628480/ https://www.ncbi.nlm.nih.gov/pubmed/37941550 http://dx.doi.org/10.3389/fonc.2023.1293441 |
Ejemplares similares
-
Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank
por: Zhou, Zilong, et al.
Publicado: (2021) -
Application of Organoid Models in Prostate Cancer Research
por: Zhou, Ligui, et al.
Publicado: (2021) -
Preclinical investigation of patient-derived cervical cancer organoids for precision medicine
por: Seol, Hyang Sook, et al.
Publicado: (2022) -
Organoid modeling for cancer precision medicine
por: Cantrell, Michael A, et al.
Publicado: (2015) -
Patient‐derived organoids as a preclinical platform for precision medicine in colorectal cancer
por: Cho, Young‐Won, et al.
Publicado: (2022)